PURPOSE: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stageIII epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P). PATIENTS AND METHODS: Single nucleotide polymorphism analysis was carried out by direct pyrosequencing at two sites (codon 118 and C8092A) in ERCC1 in leukocyte DNA from women who participated in the Gynecologic Oncology Group (GOG) phase III protocol-172 and were randomly assigned to intraperitoneal or intravenous C+P. RESULTS: ERCC1 genotyping was performed in 233 of the 429 women who participated in GOG-172. The genotype distribution at codon 118 was 17% with C/C, 43% with C/T, and 40% with T/T, and the genotype distribution at C8092A was 56% with C/C, 37% with C/A, and 7% with A/A. Adjusted Cox regression analysis revealed that the codon 118 polymorphism in ERCC1 was not significantly associated with disease progression or death. Women with the C8092A C/A or A/A genotypes compared with the C/C genotype had an increased risk of disease progression (hazard ratio [HR] = 1.44; 95% CI, 1.06 to 1.94; P = .018) and death (HR = 1.50; 95% CI, 1.07 to 2.09; P = .018). Median PFS and OS were 6 and 17 months shorter for women with the C8092A C/A or A/A genotypes versus the C/C genotype, respectively. CONCLUSION: Although the ERCC1 codon 118 polymorphism does not seem to be associated with clinical outcome, the C8092A polymorphism was an independent predictor of PFS and OS in women with optimally resected EOC.
RCT Entities:
PURPOSE: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P). PATIENTS AND METHODS: Single nucleotide polymorphism analysis was carried out by direct pyrosequencing at two sites (codon 118 and C8092A) in ERCC1 in leukocyte DNA from women who participated in the Gynecologic Oncology Group (GOG) phase III protocol-172 and were randomly assigned to intraperitoneal or intravenous C+P. RESULTS:ERCC1 genotyping was performed in 233 of the 429 women who participated in GOG-172. The genotype distribution at codon 118 was 17% with C/C, 43% with C/T, and 40% with T/T, and the genotype distribution at C8092A was 56% with C/C, 37% with C/A, and 7% with A/A. Adjusted Cox regression analysis revealed that the codon 118 polymorphism in ERCC1 was not significantly associated with disease progression or death. Women with the C8092A C/A or A/A genotypes compared with the C/C genotype had an increased risk of disease progression (hazard ratio [HR] = 1.44; 95% CI, 1.06 to 1.94; P = .018) and death (HR = 1.50; 95% CI, 1.07 to 2.09; P = .018). Median PFS and OS were 6 and 17 months shorter for women with the C8092A C/A or A/A genotypes versus the C/C genotype, respectively. CONCLUSION: Although the ERCC1 codon 118 polymorphism does not seem to be associated with clinical outcome, the C8092A polymorphism was an independent predictor of PFS and OS in women with optimally resected EOC.
Authors: J Bellmunt; L Paz-Ares; M Cuello; F L Cecere; S Albiol; V Guillem; E Gallardo; J Carles; P Mendez; J J de la Cruz; M Taron; R Rosell; J Baselga Journal: Ann Oncol Date: 2007-01-17 Impact factor: 32.976
Authors: P Ceppi; M Volante; S Novello; I Rapa; K D Danenberg; P V Danenberg; A Cambieri; G Selvaggi; S Saviozzi; R Calogero; M Papotti; G V Scagliotti Journal: Ann Oncol Date: 2006-09-15 Impact factor: 32.976
Authors: D Isla; C Sarries; R Rosell; G Alonso; M Domine; M Taron; G Lopez-Vivanco; C Camps; M Botia; L Nuñez; M Sanchez-Ronco; J J Sanchez; M Lopez-Brea; I Barneto; A Paredes; B Medina; A Artal; P Lianes Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: Jennifer M Rubatt; Kathleen M Darcy; Chunqiao Tian; Franco Muggia; Rajiv Dhir; Deborah K Armstrong; Michael A Bookman; Laura J Niedernhofer; Julie Deloia; Michael Birrer; Thomas Carl Krivak Journal: Gynecol Oncol Date: 2012-01-16 Impact factor: 5.482
Authors: Julie A Deloia; Nikhil R Bhagwat; Kathleen M Darcy; Mary Strange; Chunquio Tian; Kevin Nuttall; Thomas C Krivak; Laura J Niedernhofer Journal: Gynecol Oncol Date: 2012-05-16 Impact factor: 5.482
Authors: P Biason; C M Hattinger; F Innocenti; R Talamini; M Alberghini; K Scotlandi; C Zanusso; M Serra; G Toffoli Journal: Pharmacogenomics J Date: 2011-08-09 Impact factor: 3.550
Authors: Prema Peethambaram; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Kimberly R Kalli; Elaine A Elliott; Ann L Oberg; Kristin L White; David N Rider; Gary L Keeney; Julie M Cunningham; Lynn C Hartmann; Ellen L Goode Journal: Int J Mol Epidemiol Genet Date: 2011-05-02